Сердечный белок, связывающий жирные кислоты, в диагностике и прогнозировании течения острого коронарного синдрома: новые возможности или утраченные иллюзии


В.А. Кокорин

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» (РНИМУ) Минздрава России, Москва
В статье обсуждаются современные представления о диагностической и прогностической значимости определения сердечного белка, связывающего жирные кислоты (сБСЖК), в качестве маркера повреждения и некроза миокарда у больных с подозрением на острый коронарный синдром (ОКС). Приведены данные по сравнению сБСЖК с более распространенными в настоящее время биомаркерами. Рассмотрены возможности мультимаркерного подхода, включающего определение сБСЖК, для диагностики или исключения различных форм ОКС. Отдельное внимание уделено отечественному опыту применения экспресс-тестов для качественного определения сБСЖК как на стационарном, так и на амбулаторном этапах оказания медицинской помощи. Полученные высокие показатели по основным характеристикам таких тестов позволяют рекомендовать их для более широкого применения в клинической практике, особенно в ранние сроки ОКС. Дальнейшие исследования позволят более точно определить место сБСЖК в диагностике и прогнозировании течения ОКС.
Ключевые слова: прогнозирование течения, сердечный белок, ранняя диагностика, связывающий жирные кислоты, острый коронарный синдром
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  • Здравоохранение в России. 2017: Стат. сб. / Росстат. М., 2017. 170 с.
  • Thygesen K., Alpert J.S., Jaffe A.S. et al. Third Universal Definition of Myocardial Infarction. Eur Heart J. 2012;33:2551–67.
  • Kleine A.H., Glatz J.F., van Nieuwenhoven F.A. et al. Release of heart fatty acid-binding protein after acute myocardial infarction in man. Mol Cell Biochem 1992; 116:155-162.
  • Hamm C.W., Bassand J.-P., Agewall S. et al. Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without peristent ST segment elevation. Eur Heart J. 2011;32:2999-3054.
  • Ishii J., Wang J. H., Naruse H. et al. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem. 1997;43(8 Pt 1):1372-8.
  • Okamoto F., Sohmiya K., Ohkaru Y. et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med. 2000;38(3):231-8.
  • Chan C.P., Sanderson J.E., Glatz J.F. et al. A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol. 2004;93(5):388-97.
  • McCann C.J., Glover B.M., Menown I.B. et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008; 29(23):2843-2850.
  • Body R., McDowell G., Carley S. et al. A FABP-ulous ‘rule out’ strategy? Heart fatty acid binding protein and troponin for rapid exclusion of acute myocardial infarction. Resuscitation. 2011;82(8):1041-6.
  • McMahon C.G., Lamont J.V., Curtin E. et al. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med. 2012;30(2):267-74.
  • Pyati A.K., Devaranavadagi B.B., Sajjannar S.L. et al. Heart-type fatty acid binding protein: a better cardiac biomarker than CK-MB and myoglobin in the early diagnosis of acute myocardial infarction. J Clin Diagn Res. 2015;9(10):BC08-11.
  • Vupputuri A., Sekhar S., Krishnan S. et al. Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain. Indian Heart J. 2015;67(6):538-42.
  • Kabekkodu S.P., Mananje S.R., Saya R.P. A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. J Clin Diagn Res. 2016;10(1):OC07-10.
  • Cubranic Z., Madzar Z., Matijevic S. et al. Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome. Biochem Med (Zagreb). 2012;22(2):225-36.
  • Charpentier S., Maupas-Schwalm F., Cournot M. et al. Diagnostic accuracy of quantitative heart-fatty acid binding protein assays compared with CardioDetect in the early detection of acute coronary syndrome. Arch. Cardiovasc Dis. 2011;104(10):524-9.
  • Chandran P.A., Wani B.A., Satish O.S. et al. Diagnosis of non-ST-elevation acute coronary syndrome by the measurement of heart-type fatty acid binding protein in serum: a prospective case control study. J Biomark. 2014;2014:624930.
  • Inoue K., Suwa S., Ohta H. et al. Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain. Circ J. 2011;75(12):2813-20.
  • Cappellini F., Da Molin S., Signorini S. et al. Heart-type fatty acid-binding protein may exclude acute myocardial infarction on admission to emergency department for chest pain. Acute Card Care. 2013;15(4):83-7.
  • Uitterdijk A., Sneep S., van Duin R.W. et al. Serial measurement of hFABP and high-sensitivity troponin I post-PCI in STEMI: how fast and accurate can myocardial infarct size and no-reflow be predicted? Am J Physiol Heart Circ Physiol. 2013;305(7):H1104-10.
  • Kellens S., Verbrugge F.H., Vanmechelen M. et al. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2016;5(2):177-84.
  • Keller T., Zeller T., Ojeda F.M. et al. Serial changes in highly sensitive troponin I assays and early diagnosis of myocardial infarction. J Am Med Assoc. 2011;306:2684–93.
  • Willemsen R.T., van Severen E., Vandervoort P.M. et al. Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: optimal cut-off point, diagnostic value and future opportunities in primary care. Eur J Gen Pract. 2015;21(3):156-63.
  • Zeren G., Erer H.B., Kırış T. et al. Relation of heart-type fatty acid-binding protein with the degree and extent of atherosclerosis in patients with non-ST elevation acute coronary syndrome. Turk Kardiyol Dern Ars. 2013;41(7):610-6.
  • Kitamura M., Hata N., Takayama T. et al. Different characteristics of cardiac biomarkers to decide and predict the culprit lesions in patients with suspicious acute coronary syndrome. Heart Vessels. 2016;31(6):907-17.
  • Carroll C., Al Khalaf M., Stevens J.W. et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emerg Med J. 2013;30(4):280-6.
  • Lippi G., Mattiuzzi C., Cervellin G. Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction. Clin Biochem. 2013;46(1-2):26-30.
  • Xu L.Q., Yang Y.M., Tong H. et al. Early diagnostic performance of heart-type fatty acid binding protein in suspected acute myocardial infarction: evidence from a meta-analysis of contemporary studies. Heart Lung Circ. 2017; doi: 10.1016/j.hlc.2017.03.165.
  • Figiel L., Wraga M., Bednarkiewicz Z. et al. Direct comparison of the diagnostic value of point-of-care tests detecting heart-type fatty acid binding protein or glycogen phosphorylase isoenzyme BB in patients with acute coronary syndromes with persistent ST-segment elevation. Kardiol. Pol. 2011;69(1):1-6.
  • Gerede D.M., Güleç S., Kiliçkap M. et al. Comparison of a qualitative measurement of heart-type fatty acid-binding protein with other cardiac markers as an early diagnostic marker in the diagnosis of non-ST-segment elevation myocardial infarction. Cardiovasc J Afr. 2015;26(6):204-9.
  • El Missiri A., Okasha N., Badr T. Heart-type fatty acid-binding protein detects more patients with non-ST segment elevation myocardial infarction compared to troponin-T. Egypt Heart J. 2016;68(1):11-6.
  • Hamza M., Demerdash S., Ibrahim M. Heart-type fatty acid-binding protein as a diagnostic biochemical marker for early detection of myocardial infarction. Acta Cardiol. 2016;71(5):537-41.
  • Abbasi W.A., Saleem M., Rasheed S. et al. Utility of heart type fatty acid binding protein (H-FABP) point of care test in the early hours of STEMI compared with troponin-I in Pakistani population. J Ayub Med Coll Abbottabad. 2017;29(1):107-111.
  • Bruins Slot M.H., Rutten F.H., van der Heijden G.J. et al. Diagnostic value of a heart-type fatty acid-binding protein (H-FABP) bedside test in suspected acute coronary syndrome in primary care. Int J Cardiol. 2013;168(2):1485-9.
  • Willemsen R.T., van Severen E., Vandervoort P.M. et al. Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: optimal cut-off point, diagnostic value and future opportunities in primary care. Eur J Gen Pract. 2015;21(3):156-63.
  • Кокорин В.А. Российский опыт качественного определения содержания сердечного белка, связывающего жирные кислоты, для ранней диагностики инфаркта миокарда. Фарматека. 2017;10(343):39-44.
  • Мартынов А.И., Воевода М.И., Арутюнов Г.П. и др. Клиническая эффективность ранней диагностики острого инфаркта миокарда с помощью белка, связывающего жирные кислоты. Российский кардиологический журнал, 2012;3:7-11.
  • Ярохно Н.Н., Большакова И.А., Балабушевич А.В. и др. Оценка эффективности ранней стратификации риска с применением сердечного белка, связывающего жирные кислоты, у больных с подозрением на острый коронарный синдром без подъема сегмента ST в условиях скорой медицинской помощи. Врач скорой помощи. 2013;6:21-25.
  • Плавунов Н.Ф., Кадышев В.А., Соколов А.Ю. и др. Апробация теста «КардиоБСЖК» в практике скорой медицинской помощи при дифференциальной диагностике острого коронарного синдрома. Скорая медицинская помощь. 2014;4:31-36.
  • Jacobs L.H., van Borren M., Gemen E. et al. Rapidly rule out acute myocardial infarction by combining copeptin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015;52(Pt 5):550-61.
  • Banu S., Tanveer S., Manjunath C.N. Comparative study of high sensitivity troponin T and heart-type fatty acid-binding protein in STEMI patients. Saudi J Biol Sci. 2015;22(1):56-61.
  • Collinson P.O., Gaze D.C., Thokala P. et al. Randomised assessment of treatment using panel assay of cardiac markers - contemporary biomarker evaluation (RATPAC CBE). Health Technol Assess. 2013;17(15):V-VI, 1-122.
  • Gami B.N., Patel D.S., Haridas N. et al. Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome. J Clin Diagn Res. 2015;9(1):BC22-4.
  • Reddy L.L., Shah S.A., Dherai A.J. et al. Troponin T and heart type fatty acid binding protein (H-FABP) as biomarkers in patients presenting with chest pain. Indian J Clin Biochem. 2016;31(1):87-92.
  • Schoenenberger A.W., Stallone F., Walz B. et al. Incremental value of heart-type fatty acid-binding protein in suspected acute myocardial infarction early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016;5(2):185-92.
  • Banu K.Y., Niyazi O.D., Erdem C. et al. Value of heart-type fatty acid-binding protein (H-FABP) for emergency department patients with suspected acute coronary syndrome. Afr Health Sci. 2014;14(3):757-62.
  • Liou K., Ho S., Ooi S.Y. Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis. Ann Clin Biochem. 2015;52(Pt 3):370-81.
  • Dupuy A.M., Cristol J.P., Kuster N. et al. Performances of the heart fatty acid protein assay for the rapid diagnosis of acute myocardial infarction in ED patients. Am J Emerg Med. 2015;33(3):326-30.
  • Young J.M., Pickering J.W., George P.M. et al. Heart fatty acid binding protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emerg Med. 2016;16(1):34.
  • Body R., Dixon D., Burrows G. et al. Economic evaluation of a heart-type fatty acid binding protein based protocol for rapid chest pain assessment. 14th International Conference on Emergency Medicine. Acad Emerg Med. 2012;19(6):746-7.
  • O’Donoghue M., de Lemos J.A., Morrow D.A. et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114:550–557.
  • Onda T., Inoue K., Suwa S. et al. Reevaluation of cardiac risk scores and multiple biomarkers for the prediction of first major cardiovascular events and death in the drug-eluting stent era. Int J Cardiol. 2016;219:180-5.
  • Body R., Burrows G., Carley S. et al. The Manchester Acute Coronary Syndromes (MACS) decision rule: validation with a new automated assay for heart-type fatty acid binding protein. Emerg Med J. 2015;32(10):769-74.
  • Greenslade J.H., Nayer R., Parsonage W. et al. Validating the Manchester Acute Coronary Syndromes (MACS) and Troponin-only Manchester Acute Coronary Syndromes (T-MACS) rules for the prediction of acute myocardial infarction in patients presenting to the emergency department with chest pain. Emerg Med J. 2017;34(8):517-23.
  • Jones J.D., Chew P.G., Dobson R. et al. The prognostic value of heart type fatty acid binding protein in patients with suspected acute coronary syndrome: A systematic review. Curr Cardiol Rev. 2017;13(3):189-98.
  • Hai-Long W., Xiao-Hua P., Jian-Jun Y. The prognostic value of heart-type fatty acid binding protein in patients with acute coronary syndrome. J Coll Physicians Surg Pak. 2018;28(1):56-60.


    • Об авторах / Для корреспонденции

    Валентин Александрович Кокорин, к.м.н., доцент кафедры госпитальной терапии № 1 ФГБОУ ВО РНИМУ
    им. Н.И. Пирогова Минздрава России, г. Москва. E-mail: valentinkokorin@yahoo.com, http://orcid.org/0000-0001-8614-6542


    Похожие статьи

    К содержанию номера

    Бионика Медиа